Extract
Pulmonary embolism is the third most frequent acute cardiovascular disease with an annual incidence of approximately 100 cases per 100 000 population and an annual mortality of ≥7 deaths per 100 000 population in the European region [1, 2]. Initial management is adjusted to the risk of in-hospital death or early complications, which depend both on the severity of pulmonary embolism and the presence of comorbidities [3].
Abstract
Early discharge and home treatment of acute pulmonary embolism in fragile patients appears to be feasible and acceptably safe. Caution is warranted due to the higher risk of major bleeding among fragile patients. https://bit.ly/2YtStiU
Footnotes
The HoT-PE Investigators: Stavros V. Konstantinides, Rupert Martin Bauersachs, Christoph Bode, Michael Christ, Christine Espinola-Klein, Annette Geibel, Mareike Lankeit, Michael Pfeifer, Sebastian Schellong, Philipp S. Wild, Harald Binder, Kurt Quitzau, Nadine Martin, Dorothea Becker, Stefano Barco, Irene Schmidtmann, Toni Anusic, Martin Schwaiblmair, Ursula Rauch-Kröhnert, Martin Möckel, Johannes Brachmann, Jan Beyer-Westendorf, Daniel Duerschmied, Sabine Blaschke, Marius M. Hoeper, Evangelos Giannitis, Klaus Empen, Rainer Schmiedel, Ulrich Hoffman, Ibrahim Akin, Andreas Meyer, Sabine Genth-Zotz, Joachim Ficker, Tobias Geisler, Matthias Held, Cecilia Becattini, Ludovica Cimini, Jörg Herold, Walter Ageno, Rodolfo Sbrojavacca, Enrico Bernardi, Giuseppe Bettoni, Roberto Cosentini, Paolo Moscatelli, Cinzia Nitti, Maria Pazzaglia, Raffaele Pesavento, Alessandra Ascani, Francesca Cortellaro, Nicola Montano, Peter E. Westerweel, Pedro Ruiz-Artacho, David Jiménez, Aitor Ballaz-Quincoces, Raquel Lopez Reyes, Remedios Otero, Candida Fonseca, Tiago Judas, Inês Araujo, Sergio Batista, Fabienne Goncalves, Veli-Pekka Harjola, Pirjo Mustonen, Georgios Hahalis, Athanassios Manginas, Konstantinos Gougoulianis, Athanasios Manolis, Michael Czihal, Tobias J. Lange, Raoul Stahrenberg, Thomas Meinertz, Menno V. Huisman, Paolo Prandoni, Walter Lehmacher, Stanislav Gorbulev and Kai Kronfeld.
Conflict of interest: L. Hobohm reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; personal fees from MSD and Actelion, outside the submitted work.
Conflict of interest: T. Anušic reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study.
Conflict of interest: S.V. Konstantinides reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; grants and personal fees from Boehringer Ingelheim, Bayer, Daiichi-Sankyo and Pfizer – Bristol-Myers Squibb, personal fees from MSD, grants from Actelion, outside the submitted work.
Conflict of interest: S. Barco reports grants from German Federal Ministry of Education and Research (BMBF 01EO1503), during the conduct of the study; personal fees for lectures and travel costs from Bayer Health Care, personal fees for lectures from BTG Pharmaceuticals, Leo Pharma and Daiichi-Sankyo, outside the submitted work.
Support statement: The work of Lukas Hobohm, Stavros V. Konstantinides and Stefano Barco is supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 and 01EO1503). The sponsor, the University Medical Center Mainz (Germany), obtained the study drug and a grant from Bayer AG, the market authorisation holder of rivaroxaban. The authors were entirely responsible for the design and conduct of the study, statistical analysis, interpretation of results and drafting of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received March 12, 2020.
- Accepted April 29, 2020.
- Copyright ©ERS 2020